Research and Development Archives

March 14, 2022

Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022 CHICAGO and TORONTO, March 14, 2022 (GLOBE…

https://wesanahealth.com/wp-content/themes/impeka/impeka/images/empty/thumbnail.jpg 150 150 Wesana Health Wesana Health https://wesanahealth.com/wp-content/themes/impeka/impeka/images/empty/thumbnail.jpg March 14, 2022 March 25, 2022

Press Releases Research and Development

January 18, 2022

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced…

Press Releases Research and Development

January 11, 2022

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven…